LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma is a phase 3 interventional study registered as NCT07362186, led by LaNova Medicines, and recruiting on the registry. Official title: A Phase III, Open-Label, Multicenter, Randomised, Parallel-Group Study to Evaluate the Efficacy and Safety of LM-108 in Combination With Toripalimab Versus Paclitaxel Injection as Second-Line Therapy for CCR8-Positive Locally Advanced or Metastatic Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. Planned enrolment is 400 participants (estimated). The study started in 2026-04-30 and primary completion is expected in 2028-08-17. No results have been posted on ClinicalTrials.gov.